Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Pfizer’s Remicade biosimilar receives Crohn’s trial boost

Inflectra shown to be similar to originator in data presented at ECCO in Barcelona

MHRA launches medicines regulation blog as Brexit looms

MedRegs will provides insight into its latest regulatory thinking

AstraZeneca AZ

AZ agrees to $320m deal for Zoladex

TerSera Therapeutics acquires rights to oncology drug in US and Canada

- PMLiVE

Lions Health announces jury presidents

McCann's June Laffey and Serviceplan Health & Life's Mike Rogers to lead

Cell and gene therapies: on course for commercial success?

Funding and reimbursement of cell and gene therapies pose a major challenge as payers consider how to evaluate a commercial proposition that is completely divergent from the traditional pharmaceutical model....

Greenleaf Health appoints drug and biological products principal

Dr John Jenkins joins the FDA regulatory consulting firm

- PMLiVE

BioMarin’s chief commercial officer joins True North’s board

Jeff Ajer brings over 20 years of industry experience to the biotech

Make Anthill your strategic partner in Barcelona

We are excited to attend and exhibit at eyeforpharma Barcelona 2017 (March 14-16th), and present two multichannel strategy workshops.

Anthill Agency

ABPI London offices

Norgine UK re-joins ABPI

Firm resigned its membership in 2008 in protest over lack of representation

- PMLiVE

TiGenix cell therapy for Crohn’s fistulas shows long-term benefit

Phase III data for the Takeda-partnered drug raises hopes for upcoming EU approval

- PMLiVE

AZ moves closer to Lynparza filing in breast cancer

PARP inhibitor showed “statistically-significant and clinically-meaningful” improvement in phase III trial

- PMLiVE

Top ten tech trends

As technology continues to have a huge impact on society’s mental and physical health, what’s on the horizon for 2017?

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links